Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Biomarker-Driven Early Clinical Trials in Oncology

(2010) Daniel S. W. Tan et al.   CANCER JOURNAL

Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis

(2010) J. V. Olsen et al.   Science Signaling

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Sensitive multiplexed analysis of kinase activities and activity-based kinase identification

(2009) Kazuishi Kubota et al.   NATURE BIOTECHNOLOGY

The nuts and bolts of AGC protein kinases

(2009) Laura R. Pearce et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model

(2008) Mark T. Bilodeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Therapeutic strategies for inhibiting oncogenic BRAF signaling

(2008) Ensar Halilovic et al.   CURRENT OPINION IN PHARMACOLOGY

The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry

(2008) Judit Villén et al.   Nature Protocols

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE